Search - tctmd.com

Displaying 21 - 40 of 106

Sort: Relevancy | Date

News

Tastes Like Ticagrelor: Mouth-Dissolving Pills Match Standard Ones in ACS

Yael L. Maxwell

July 13, 2021

News Daily News

ISAR-REACT 5: Subanalysis of PCI Patients Confirms Prasugrel Superiority

Yael L. Maxwell

July 01, 2021

Crushing Prasugrel Tabs Ups Platelet Inhibition Following Primary PCI

News Daily News

Crushed Prasugrel in the Ambulance Ups Platelet Inhibition in Primary PCI

Yael L. Maxwell

June 22, 2021

News Conference News TCT 2020

Bivalirudin vs Heparin Patient-Level Meta-analysis Stirs an Old Debate

Shelley Wood

October 14, 2020

News Conference News TCT 2020

No Reperfusion Benefit From Crushed Prasugrel Prior to PCI: COMPARE CRUSH

L.A. McKeown

October 14, 2020

Presentation TCT 2020

TCT 065: Cangrelor Use Patterns and Transition to Oral P2Y12 Inhibitors Among Patients With Myocardial Infarction: Early Results From the Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes (CAMEO) Registry

Presenter: Jennifer Rymer

October 14, 2020

News Conference News EuroPCR 2020

Tirofiban Provides Better Platelet Inhibition Than Cangrelor in STEMI Patients

Michael O'Riordan

June 30, 2020

News Daily News

Injectable P2Y12 Inhibitor Selatogrel Shows Promise in Acute MI

Yael L. Maxwell

June 03, 2020

Presentation JIM 2020

Clinical Crossroads On Optimal Antithrombotic Therapy In Patients Treated With Pci Intravenous Antiplatelet Therapy In High Risk Acs

Presenter: Dominick Angiolillo

February 13, 2020

News Daily News

Clopidogrel Interaction With Morphine in ACS Linked to More Ischemic Events

Shelley Wood

January 20, 2020

News Daily News

CEC Identifies ‘Prognostically Important’ MIs: CHAMPION PHOENIX

Michael O'Riordan

July 30, 2019

News Conference News SCAI 2019

Cancer and CV Disease Care: What’s Known? What Lies Ahead for Cardio-Oncology?

Yael L. Maxwell

May 30, 2019

Presentation JIM 2019

Cangrelor is ready for the prime time

Presenter: Giuseppe Musumeci

February 15, 2019

News Daily News

Crushing It: Cangrelor and Ticagrelor Can Be Used Together Safely in STEMI, Small Study Hints

Todd Neale

January 14, 2019

Presentation

Platelet Inhibition With Cangrelor and Crushed Ticagrelor in STEMI Patients Undergoing Primary PCI

January 14, 2019

Presentation TCT Abstracts Posters 2018

Cost-Consequence Analysis of Cangrelor Use in High Angiographic Risk Percutaneous Coronary Intervention (PCI) Patients: A US Hospital Perspective

Presenter: Ivar S Jensen

September 25, 2018

Presentation TCT 2018

Utility of Cangrelor During PCI and Bridging Who Benefits Most?

Presenter: John A. Bittl, C. Michael Gibson, Deepak L. Bhatt

September 23, 2018

News Conference News ESC 2018

New ESC/EACTS Revascularization Guidelines Make Room for Radial First, STICH, and DES for All

Michael O'Riordan

August 29, 2018

News Conference News ESC 2018

Pretreatment With P2Y12 Inhibitors Questioned Anew in SCAAR

Shelley Wood

August 28, 2018

News Daily News

Women Underrepresented in Pivotal Studies Leading to FDA Drug Approval

Michael O'Riordan

May 01, 2018

Advertisement

Tastes Like Ticagrelor: Mouth-Dissolving Pills Match Standard Ones in ACS

ISAR-REACT 5: Subanalysis of PCI Patients Confirms Prasugrel Superiority

Crushed Prasugrel in the Ambulance Ups Platelet Inhibition in Primary PCI

Bivalirudin vs Heparin Patient-Level Meta-analysis Stirs an Old Debate

No Reperfusion Benefit From Crushed Prasugrel Prior to PCI: COMPARE CRUSH

TCT 065: Cangrelor Use Patterns and Transition to Oral P2Y12 Inhibitors Among Patients With Myocardial Infarction: Early Results From the Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes (CAMEO) Registry

Tirofiban Provides Better Platelet Inhibition Than Cangrelor in STEMI Patients

Injectable P2Y12 Inhibitor Selatogrel Shows Promise in Acute MI

Clinical Crossroads On Optimal Antithrombotic Therapy In Patients Treated With Pci Intravenous Antiplatelet Therapy In High Risk Acs

Clopidogrel Interaction With Morphine in ACS Linked to More Ischemic Events

CEC Identifies ‘Prognostically Important’ MIs: CHAMPION PHOENIX

Cancer and CV Disease Care: What’s Known? What Lies Ahead for Cardio-Oncology?

Cangrelor is ready for the prime time

Crushing It: Cangrelor and Ticagrelor Can Be Used Together Safely in STEMI, Small Study Hints

Platelet Inhibition With Cangrelor and Crushed Ticagrelor in STEMI Patients Undergoing Primary PCI

Cost-Consequence Analysis of Cangrelor Use in High Angiographic Risk Percutaneous Coronary Intervention (PCI) Patients: A US Hospital Perspective

Utility of Cangrelor During PCI and Bridging Who Benefits Most?

New ESC/EACTS Revascularization Guidelines Make Room for Radial First, STICH, and DES for All

Pretreatment With P2Y12 Inhibitors Questioned Anew in SCAAR

Women Underrepresented in Pivotal Studies Leading to FDA Drug Approval

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content